Longevity Therapeutics

Memo

The inaugural Longevity Therapeutics 2019 will bring together the leading biotech drug developers, academics, investors and pharma companies endeavoring to develop innovative therapies targeting age-related conditions. Join them to collaboratively tackle specific challenges faced to develop these therapies – from discovery, to preclinical activities, translational research, clinical development, regulatory and commercial considerations – and uncover the details behind the latest developments in this space. Prices: Early Rate: USD 1799.0Standard Rate: USD 2099.0 On Tuesday January 29, 2019 at 8:00 am (ends Thursday January 31, 2019 at 5:00 pm) URLs: Brochure: https://go.evvnt.com/286192-0?pid=5569 Tickets: https://go.evvnt.com/286192-1?pid=5569 Speakers: Aubrey de Grey - AgeX Therapeutics, Judith Campisi - Buck Institute for Research on Aging, Nathaniel David - Unity Biotechnology, Nir Barzilai - Albert Einstein College of Medicine, Samuel Agus - Biophytis, Steven Braithwaite - Alkahest Inc., Ronald Kohanski - National Institute on Aging, NIH, Mark Bamberger - Stealth BioTherapeutics, Marc Ramis-Castelltort - Senolytic Therapeutics Inc., Lorna Harries - University of Exeter Medical School, Lindsay Wu - UNSW Sydney, Life Biosciences, Kristen Fortney - BioAge Labs, Kelsey Moody - Antoxerene/Ichor Therapeutics Venue details: Argonaut Hotel, 495 Jefferson Street, San Francisco, 94109, United States